Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļA
āļāļ·āđāļāļāļĢāļīāļĐāļąāļAgilent Technologies Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļNov 18, 1999
āļāļĩāļāļĩāđāļMcdonnell (Padraig)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ- -
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļNov 18
āļāļĩāđāļāļĒāļđāđ5301 Stevens Creek Blvd
āđāļĄāļ·āļāļSANTA CLARA
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX NASDAQ Basic NYSE
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ95051
āđāļāļĢāļĻāļąāļāļāđ14083458886
āđāļ§āđāļāđāļāļāđhttps://www.agilent.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļA
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļNov 18, 1999
āļāļĩāļāļĩāđāļMcdonnell (Padraig)
Mr. Boon Hwee Koh
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
Mr. Rodney Gonsalves
Vice President, Corporate Controller, Principal Accounting Officer
Vice President, Corporate Controller, Principal Accounting Officer
Mr. Padraig Mcdonnell
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. George A. Scangos, Ph.D.
Dr. George A. Scangos, Ph.D.
Independent Director
Dr. Daniel K. Podolsky, M.D.
Dr. Daniel K. Podolsky, M.D.
Independent Director
Mr. Dow R. Wilson
Independent Director
Ms. Mala Anand
Independent Director
Dr. Simon May
Senior Vice President, Agilent President, Life Sciences and Diagnostics Markets Group
Senior Vice President, Agilent President, Life Sciences and Diagnostics Markets Group
Mr. Bret M. Dimarco
Senior Vice President, Chief Legal Officer, Secretary
Senior Vice President, Chief Legal Officer, Secretary
Mr. Adam Stewart Elinoff
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Boon Hwee Koh
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
Mr. Rodney Gonsalves
Vice President, Corporate Controller, Principal Accounting Officer
Vice President, Corporate Controller, Principal Accounting Officer
Mr. Padraig Mcdonnell
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. George A. Scangos, Ph.D.
Dr. George A. Scangos, Ph.D.
Independent Director
Dr. Daniel K. Podolsky, M.D.
Dr. Daniel K. Podolsky, M.D.
Independent Director
Mr. Dow R. Wilson
Independent Director
Goldman Sachs Future Health Care Equity ETF
VanEck Morningstar Wide Moat Value ETF
iShares Health Innovation Active ETF
VanEck Morningstar Wide Moat ETF
Global X Genomics & Biotechnology ETF
Invesco Zacks Mid-Cap ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Honeytree US Equity ETF
āļŠāļąāļāļŠāđāļ§āļ5.06%
First Trust Water ETF
āļŠāļąāļāļŠāđāļ§āļ4.76%
Goldman Sachs Future Health Care Equity ETF
āļŠāļąāļāļŠāđāļ§āļ3.87%
VanEck Morningstar Wide Moat Value ETF
āļŠāļąāļāļŠāđāļ§āļ3.31%
Madison Covered Call ETF
āļŠāļąāļāļŠāđāļ§āļ3.27%
iShares Health Innovation Active ETF
āļŠāļąāļāļŠāđāļ§āļ2.9%
VanEck Morningstar Wide Moat ETF
āļŠāļąāļāļŠāđāļ§āļ2.87%
Argent Mid Cap ETF
āļŠāļąāļāļŠāđāļ§āļ2.57%
Global X Genomics & Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ2.4%
Invesco Zacks Mid-Cap ETF
āļŠāļąāļāļŠāđāļ§āļ2.29%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
1.31B
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
A.NB Final Cash Dividend of gross USD 0.248 paid on Oct 22, 2025 going ex on Sep 30, 2025 with reinvestment option
A.NB Interim Cash Dividend of gross USD 0.248 paid on Jul 23, 2025 going ex on Jul 01, 2025 with reinvestment option
A.NB Interim Cash Dividend of gross USD 0.248 paid on Apr 23, 2025 going ex on Apr 01, 2025 with reinvestment option
A.NB Interim Cash Dividend of gross USD 0.248 paid on Jan 22, 2025 going ex on Dec 31, 2024 with reinvestment option
A.NB Final Cash Dividend of gross USD 0.236 paid on Oct 23, 2024 going ex on Oct 01, 2024 with reinvestment option
A.NB Interim Cash Dividend of gross USD 0.236 paid on Jul 24, 2024 going ex on Jul 02, 2024
A.NB Interim Cash Dividend of gross USD 0.236 paid on Apr 24, 2024 going ex on Apr 01, 2024
A.NB Interim Cash Dividend of gross USD 0.236 paid on Jan 24, 2024 going ex on Dec 29, 2023
A.NB Final Cash Dividend of gross USD 0.225 paid on Oct 25, 2023 going ex on Oct 02, 2023 with reinvestment option
A.NB Interim Cash Dividend of gross USD 0.225 paid on Jul 26, 2023 going ex on Jun 30, 2023 with reinvestment option
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ